Show simple item record

dc.contributor.authorJambhrunkar, M
dc.contributor.authorYang, Y
dc.contributor.authorYu, M
dc.contributor.authorZhang, M
dc.contributor.authorAbbaraju, PL
dc.contributor.authorGhosh, T
dc.contributor.authorKalantari, M
dc.contributor.authorWang, Y
dc.contributor.authorMcMillan, NAJ
dc.contributor.authorYu, C
dc.date.accessioned2020-10-13T23:45:25Z
dc.date.available2020-10-13T23:45:25Z
dc.date.issued2020
dc.identifier.issn2590-0498en_US
dc.identifier.doi10.1016/j.mtadv.2020.100069en_US
dc.identifier.urihttp://hdl.handle.net/10072/398348
dc.description.abstractNanomaterials have provided an emerging solution to improve the efficacy of cancer vaccines against malignant tumors. However, developing nanoparticles possessing both potent immunoadjuvant and co-delivery activities without tedious functionalization remains challenging. In the present work, we report that pristine benzene-bridged mesoporous organosilica nanoparticles are a novel immunoadjuvant and co-delivery platform for both antigen and cytosine-phosphodiester-guanine oligodeoxynucleotide (CpG, a toll-like receptor 9 agonist). It is shown that the chemical compositions of bridged organosilica framework (–Si–R–Si–OH, R = benzene, ethylene) have a significant impact on their functionalities. When benzene bridge groups are present in the framework, pristine nanoparticles with large mesopores and high pore volumes are able to stimulate the maturation of dendritic cells, and efficiently co-encapsulate ovalbumin (OVA) and CpG for delivery into immune cells, leading to a superior tumor inhibition performance in an aggressive OVA-expressed B16F10 melanoma model, with 100% tumor-free mice in 25 days. Our study provides new knowledge in the design of effective cancer nanovaccines.en_US
dc.description.peerreviewedYesen_US
dc.languageEnglishen_US
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofpagefrom100069en_US
dc.relation.ispartofjournalMaterials Today Advancesen_US
dc.relation.ispartofvolume6en_US
dc.subject.fieldofresearchMedical and Health Sciencesen_US
dc.subject.fieldofresearchcode11en_US
dc.subject.keywordsScience & Technologyen_US
dc.subject.keywordsMaterials Science, Multidisciplinaryen_US
dc.subject.keywordsMaterials Scienceen_US
dc.subject.keywordsAdjuvanten_US
dc.titlePristine large pore benzene-bridged mesoporous organosilica nanoparticles as an adjuvant and co-delivery platform for eliciting potent antitumor immunityen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Articlesen_US
dcterms.bibliographicCitationJambhrunkar, M; Yang, Y; Yu, M; Zhang, M; Abbaraju, PL; Ghosh, T; Kalantari, M; Wang, Y; McMillan, NAJ; Yu, C, Pristine large pore benzene-bridged mesoporous organosilica nanoparticles as an adjuvant and co-delivery platform for eliciting potent antitumor immunity, Materials Today Advances, 2020, 6, pp. 100069en_US
dcterms.licensehttps://creativecommons.org/licenses/by-nc-nd/4.0/en_US
dc.date.updated2020-10-13T23:41:26Z
dc.description.versionVersion of Record (VoR)en_US
gro.rights.copyright© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, providing that the work is properly cited. You may not alter, transform, or build upon this work.en_US
gro.hasfulltextFull Text
gro.griffith.authorMcMillan, Nigel


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record